Use of Anti-Idiotypes and Synthetic Peptides for Control of Human T-Lymphotropic Virus Type III Infections.
Abstract
We have investigated the potential use of synthetic peptides and anti-idiotypes (anti-Id) for controlling HIV infection. We have identified four regions of the human immunodeficiency virus type 1 HIV-1 envelope glycoprotein that have the capacity to induce neutralizing antibody responses in experimental animals. Synthetic peptides corresponding to amino acid sequences to envelope glycoproteins gp120 and gp41 were used to identify these neutralizing epitopes. One peptide corresponding to amino acid sequences 735 to 752 from gp160 was coupled to a carrier protein and used to immunize chimpanzees. The chimpanzees produced an anti-gp160 response when immunized with this peptide; however, the neutralizing antibody response was weak. These chimpanzees, along with a control peptide immunized animal, were challenged intravenously with infectious HIV. Following challenge, the chimpanzees sero-converted and developed antibody responses against gag protein products. These studies indicated that chimpanzees were not protected from HIV infection by immunization with a single synthetic peptide that previously induced neutralizing antibodies in small experimental animals. Keywords: Vaccines.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 28, 1987
- Accession Number
- ADA190454
Entities
People
- Ronald C. Kennedy
Organizations
- Texas Biomedical Research Institute